"目录号: HY-14543
Neuronal SignalingGPCR/G ProteinAutophagy-
Sertindole是5-HT2A，5-HT2C，D2和αl受体拮抗剂。
5-HT ReceptorDopamine ReceptorAutophagy
相关产品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available.Target: Multi-targetIn vitro studies showed that sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and αl adrenergic receptors. Sertindole offers an alternative treatment option for refractory patients given its good EPS profile, favorable metabolic profile, and comparable efficacy to risperidone. Due to cardiovascular safety concerns, sertindole is available as a second-line choice for patients intolerant to other antipsychotic agents [1]. Sertindole should prove to be a very useful addition to the therapeutic options available for the treatment of psychotic disorders [2]. Sertindole improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. Sertindole is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS). Thus, sertindole is a useful option in the treatment of patients with schizophrenia [3].
Clinical Trial
NCT00864045
H. Lundbeck A/S
Schizophrenia
March 2007
Phase 3
NCT00856583
H. Lundbeck A/S
Schizophrenia
July 2002
Phase 3
NCT00763438
H. Lundbeck A/S
Schizophrenia
November 2007
Phase 4
NCT00480844
Sheba Medical Center
Schizophrenia
October 2008
Phase 4
NCT02021201
Birte Glenthoj-Icahn School of Medicine at Mount Sinai-University of Copenhagen
Schizophrenia
July 2008
Phase 4
NCT00885690
University of Aarhus-Aalborg Psychiatric Hospital-Malmö University
Schizophrenia
April 2009
NCT00654706
H. Lundbeck A/S
Schizophrenia-Cognition
March 2008
Phase 3
NCT00759421
H. Lundbeck A/S
Schizophrenia
October 2006
Phase 3
NCT00759460
H. Lundbeck A/S
Schizophrenia
March 2007
Phase 3
NCT00629252
University of Zurich-University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging-H. Lundbeck A/S
Schizophrenia
February 2008
NCT00612079
University of Zurich-Psychiatric University Hospital, Zurich-H. Lundbeck A/S
Healthy
September 2007
NCT01498770
Merck Sharp & Dohme Corp.
Bipolar Disorder
April 1, 2013
NCT02374567
Hannover Medical School
Dementia-Depression-Schizophrenia-Psychosomatic Disorders-Anxiety Disorders
January 2015
Phase 3
NCT02307396
Technische Universität München
Schizophrenia-Schizophrenia and Disorders With Psychotic Features-Schizoaffective Disorders
November 2014
Phase 4
View MoreCollapse
References
[1].Juruena, M.F., E.P. de Sena, and I.R. de Oliveira, Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis, 2011. 3: p. 75-85.
[2].Kane, J.M. and C.A. Tamminga, Sertindole (Serdolect): preclinical and clinical findings of a new atypical antipsychotic. Expert Opin Investig Drugs, 1997. 6(11): p. 1729-41.
[3].Murdoch, D. and G.M. Keating, Sertindole : a review of its use in schizophrenia. CNS Drugs, 2006. 20(3): p. 233-55.